Mizuho Securities analyst Graig Suvannavejh maintained a Buy rating on Axsome Therapeutics (AXSM – Research Report) today and set a price target of $76.00. The company’s shares opened today at $47.00.
Suvannavejh covers the Healthcare sector, focusing on stocks such as Harmony Biosciences Holdings, Athira Pharma, and Cerevel Therapeutics Holdings. According to TipRanks, Suvannavejh has an average return of -2.3% and a 44.04% success rate on recommended stocks.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Axsome Therapeutics with a $97.43 average price target.
See the top stocks recommended by analysts >>
Based on Axsome Therapeutics’ latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $8.82 million and a GAAP net loss of $41.44 million. In comparison, last year the company had a GAAP net loss of $32.28 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Axsome Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing novel therapies for the management of central nervous system disorders. Its product candidates include AXS-02 and AXS-06 which are developing for multiple indications. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.
Read More on AXSM:
- Axsome Therapeutics Announces Plans to Resubmit AXS-07 NDA Based on Successful FDA Type A Meeting
- Which Alzheimer’s stock may be next to jump after Biogen’s ‘clean’ win?
- Mizuho says Biogen data will serve as catalyst for these stocks
- Axsome Therapeutics to Present at the Ladenburg Thalmann Healthcare Conference
- Axsome Therapeutics to Present at the Cowen 2nd Annual Novel Mechanisms in Neuropsychiatry Summit
